Who Owns Acuvue?

Johnson & Johnson publishes an annual ESG Performance Summary disclosing its environmental, social, and governance performance. J&J has set a goal of achieving carbon neutrality across its own operations (Scopes 1 and 2) by 2030 and to reduce value chain (Scope 3) emissions by 20 percent by 2025 relative to a 2016 baseline.

Contact lens packaging and blister packs represent a significant waste challenge for the industry. J&J Vision Care has implemented blister pack recycling programs in partnership with TerraCycle in selected markets, allowing consumers to return used Acuvue blister packs for recycling. As of May 2025, these programs operate in the United States, United Kingdom, and select other markets. J&J has committed to making Acuvue packaging recyclable or refillable in major markets.

Johnson & Johnson Vision Care's manufacturing facilities in Jacksonville and Limerick operate under ISO 14001 environmental management certification. J&J is a member of the Ellen MacArthur Foundation's New Plastics Economy Global Commitment.

The Acuvue OASYS with Transitions Light Intelligent Technology lens received recognition as an innovative product after its 2019 launch. The lens incorporates photochromic technology that causes the lens to automatically darken in response to UV and high-energy visible light exposure, providing a combined vision correction and light management function that had not previously been available in a contact lens format.

J&J Vision Care has received recognition from eye care professional organizations in various markets for its professional education programs and clinical research contributions. Acuvue lenses have received FDA clearance for UV blocking as a supplemental benefit on multiple product lines, which has been noted by eye health organizations as a meaningful product innovation.

Specific independently verifiable third-party consumer product awards for Acuvue are documented across various markets, though comprehensive consolidated records are not available in a single public source as of May 2025.

Acuvue OASYS 1-Day Recall (2019): Johnson & Johnson Vision Care issued a voluntary recall in July 2019 for approximately 30 million Acuvue OASYS 1-Day with HydraLuxe lenses. The recall was initiated due to a manufacturing defect that could cause some lenses to have an incorrect base curve or diameter, potentially resulting in discomfort or vision problems. The recall was limited to specific lot numbers and was managed through contact lens providers and optometrists who had dispensed the affected products. The FDA classified the recall as Class II, meaning the product may cause temporary adverse health consequences but is unlikely to cause permanent injury.

Pricing and Antitrust: J&J Vision Care and other major contact lens manufacturers have faced antitrust scrutiny and consumer complaints regarding minimum advertised price (MAP) policies that restricted online retailers from selling contact lenses below manufacturer-set minimum prices. In 2015, the U.S. Department of Justice investigated unilateral pricing policies in the contact lens market. Retailers and consumer groups argued these policies raised prices for consumers. The contact lens industry reached a class action settlement in 2016 valued at approximately 100 million USD, though J&J Vision Care's specific role and settlement contribution were not separately disclosed.

China Market Data Privacy: J&J Vision Care, like other companies operating in China, is subject to China's Personal Information Protection Law (PIPL), which has raised compliance questions for multinational companies about how consumer data collected in China must be stored and processed. No specific enforcement action against J&J Vision Care under PIPL has been publicly documented as of May 2025.

Contact Lens Prescription Requirements Debate: J&J and other contact lens manufacturers have been involved in ongoing industry debates about contact lens prescription validity periods and whether consumers should be able to purchase lenses without a valid prescription. Consumer groups and some online retailers have argued for easier access, while eye care professionals and manufacturers have supported prescription requirements on safety grounds.